Table 3.

Scheduled and unscheduled bleeding and spotting with 2-day and 4-day ring-free intervals in participants using a contraceptive vaginal ring releasing estradiol 75 mcg, 100 mcg, or 200 mcg per day and segesterone acetate 200 mcg per day

	Ring dose	n	First 30-day extension			Second 30-day extension
			Scheduled bleeding	Unscheduled bleeding	Unscheduled spotting	Scheduled bleeding	Unscheduled bleeding	Unscheduled spotting
2 day ring-free interval	E2 75 mcg/day and SA 200 mcg/day	5	3 (60%)	0*	0 (0–11)	3 (60%)	0 (0–4)	0*
	E2 100 mcg/day and SA 200 mcg/day	6	4 (67%)	0 (0–7)	0 (0–15)	6 (100%)	0 (0–2)	0.5 (0–1)
	E2 200 mcg/day and SA 200 mcg/day	7	7 (100%)	0 (0–2)	2 (0–16)	7 (100%)	0*	3 (0–19)
4 day ring-free interval	E2 75 mcg/day and SA 200 mcg/day	6	6 (100%)	0 (0–3)	0.5 (0–12)	6 (100%)	0 (0–4)	2.5 (0–6)
	E2 100 mcg/day and SA 200 mcg/day	6	4 (67%)	0*	0.5 (0–6)	6 (100%)	0 (0–17)	0 (0–1)
	E2 200 mcg/day and SA 200 mcg/day	4	4 (100%)	0*	0 (0–4)	4 (100%)	0*	0 (0–2)

Data presented as n (%) or median (range).

SA= Segesterone Acetate; E2= Estradiol

^*No range presented because all participants reported no unscheduled bleeding or spotting